Cellares and University of Wisconsin School of Medicine and Public Health to Automate Clinical-Scale Production of CRISPR-Edited CAR-T for Solid Tumors
Partnership seeks to address cell therapy manufacturing bottlenecks and accelerate development towards clinical trials
Clinical scale manufacturing of cell therapy assets provides latest validation of Cell Shuttle's ability to empower partners to seamlessly scale production
SAN FRANCISCO & MADISON, Wis., April 10, 2025--(BUSINESS WIRE)--Cellares, the pioneering Integrated Development and Manufacturing Organization (IDMO), has announced a strategic collaboration with the University of Wisconsin School of Medicine and Public Health to automate the manufacturing of a CRISPR-edited GD2 CAR-T investigational therapy.
Cellares' Cell Shuttle™ supports early-phase biotechnology and academic cell therapy developers by providing an integrated, automated solution enabling immediate economies of scale and up to 50% lower batch prices compared to conventional CDMOs. As cell therapy assets mature, the platform ensures a seamless transition from clinical development to commercial-scale manufacturing, eliminating the need for costly process redesigns and multiple technology transfers and accelerating time-to-market for innovative therapies.
The collaboration highlights Cellares' commitment to empowering principal investigators and researchers in academic institutions by providing access to an automated, reproducible, and scalable manufacturing platform at the earliest stages of clinical development. By leveraging the Cell Shuttle's ability to simultaneously manufacture multiple cell therapy products in parallel, this partnership overcomes longstanding manufacturing bottlenecks caused by limited manufacturing capacity.
This approach shortens the journey from proof-of-concept in the lab to an investigational therapy suitable for clinical trials, ultimately aiming to improve care for patients with solid tumors. It also demonstrates how the Cell Shuttle is an automated solution for cell therapy developers of all stages, allowing them to seamlessly scale up as their manufacturing needs evolve.
"Solid tumors can be challenging to treat, and many patients have limited therapeutic options," said Fabian Gerlinghaus, Co-founder and CEO of Cellares. "By collaborating with researchers at the University of Wisconsin–Madison on their CRISPR-edited GD2 CAR-T product, we remove the manufacturing barriers that can hinder promising research. Our Cell Shuttle automates and scales production to a clinical level, which accelerates the transition from academic innovation to investigational therapy and brings hope to those who need new treatment options."
By enabling the CRISPR-edited GD2 CAR-T project at University of Wisconsin–Madison to achieve clinical-scale manufacturing earlier, the partnership can help unlock potential investment into the experimental therapy and expedite its path to initial human trials. The Cell Shuttle automates key steps that traditionally slow down development, thus enabling life-saving discoveries to advance more quickly.
Cellares encourages collaboration with researchers, academic institutions, and commercial partners at all stages of their projects, demonstrating its unwavering commitment to advancing the field of cell therapy and expanding patient access to next-generation treatments. For more information on the Cell Shuttle and Cellares' scalable manufacturing solutions, please visit cellares.com.
About University of Wisconsin School of Medicine and Public Health
The University of Wisconsin School of Medicine and Public Health is recognized as one of the nation's leading institutions in health sciences education, research, and service. Founded in 1907 as the medical school of the University of Wisconsin–Madison, in 2005 it became the nation's first school to integrate the disciplines of medicine and public health. With a deep commitment to a vision of healthy people and healthy communities, we translate discovery into application and interconnect clinical care, education and research. The school employs more than 5,400 faculty and staff and provides educational opportunities for nearly 2,400 students and postgraduate trainees. Grants awarded to School of Medicine and Public Health principal investigators in fiscal year 2023 totaled $641 million in federal and non-federal awards. Some of the nation's leading researchers, educators, and clinicians are among the faculty, including several National Medal of Science recipients and National Academy of Science honorees. For more information, visit med.wisc.edu.
About Cellares
Cellares is the first Integrated Development and Manufacturing Organization (IDMO) and takes an Industry 4.0 approach to mass manufacturing the living drugs of the 21st century. The company is developing and operating integrated technologies for cell therapy manufacturing to accelerate access to life-saving cell therapies. The company's Cell Shuttle™ integrates all the technologies required for the entire manufacturing process in a flexible and high-throughput platform that delivers true walk-away, end-to-end automation. While the Cell Shuttle™ automates cell therapy manufacturing, the Cell Q™ automates quality control at high throughput, both for in-process and batch release QC, addressing both manufacturing and QC bottlenecks. Cell Shuttles and Cell Qs will be deployed in Cellares' IDMO Smart Factories around the world, enabling each Smart Factory to produce 10 times as many cell therapy batches as conventional CDMOs with the same facility size and number of employees. Partnering with Cellares enables academic medical centers, biotechnology companies, and pharmaceutical companies to accelerate cell therapy development, scale-out manufacturing, lower process failure rates, lower manufacturing costs, and meet global patient demand.
The company is headquartered in South San Francisco, California with its first commercial-scale IDMO Smart Factory in Bridgewater, New Jersey. Cellares is building a global network of IDMO Smart Factories with additional facilities under construction in Europe and Japan. The company is backed by world-class investors and has raised over $355 million in financing.
For more information about Cellares, please visit cellares.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250410396952/en/
Contacts
Cellares Contacts
Investors:ir@cellares.com
Media:pr@cellares.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
a few seconds ago
- Business Wire
ImmunityBio Announces Phase 2 Study of ANKTIVA ® in Patients with Long COVID
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the opening of a new Phase 2 study to assess the BioShield™ platform, anchored by ANKTIVA ® (nogapendekin alfa inbakicept-pmln), in patients with long COVID. An estimated one in five Americans with a previous COVID-19 infection has long COVID, which is comprised of a broad range of symptoms that can substantially impact a patient's quality of life. Long COVID remains a significant public health challenge with no currently available established therapies. The new study, called COVID-4.019-Long, further expands the company's clinical research efforts to assess ANKTIVA's potential beyond cancer or cancer-related diseases. Currently, ANKTIVA is being evaluated alone and with other agents in multiple studies for different forms of bladder cancer, non-small cell lung cancer, glioblastoma, non-Hodgkin lymphoma, Lynch syndrome, ovarian cancer and Human Papillomavirus (HPV) associated tumors. ANKTIVA is also being studied in Human Immunodeficiency Virus (HIV) and lymphopenia. The primary objective of the exploratory, single-arm study (NCT0712372 7) is to evaluate the safety of ANKTIVA, injected under the skin (subcutaneously), in participants with long COVID. The secondary objective is to assess the effect of ANKTIVA on absolute lymphocyte count. Exploratory objectives include evaluation of ANKTIVA's ability to improve post-COVID natural killer (NK) cell and CD8+ T cell counts, and assessment of the immunological function of NK cells and CD8+ T cells. 'We are excited to study ANKTIVA for the treatment of long COVID, a substantial public health concern,' said Dr. Patrick Soon-Shiong, Founder, Executive Chairman and Global Chief Scientific and Medical Officer of ImmunityBio. 'Early in the pandemic, the common assumption was SARS-CoV-2 would prove to be a transient infection, as is the case with coronaviruses in general. But we now know viral nucleic acid and proteins can be in the gut mucosa months after infection. As such, an antiviral strategy looks insufficient to treat or cure long COVID. Based on clinical insights to date, we believe ANKTIVA may be a new therapeutic option for this chronic and potentially disabling condition by enhancing immune function, facilitating viral clearance, and addressing underlying contributions to long COVID.' The study, which is being conducted by ImmunityBio and aims to recruit up to 40 participants who meet the long COVID criteria, as established by the World Health Organization (WHO), is now accepting patients for initial screening to determine study eligibility. The safety and tolerability of ANKTIVA for long COVID is also being assessed in a separate Phase 2 study conducted at the University of California – San Francisco. Both studies are supported by ImmunityBio. To learn more, visit ANKTIVA is currently approved by the U.S. Food and Drug Administration with Bacillus Calmette-Guérin (BCG) for the treatment of patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary tumors. About Long COVID Long COVID is a serious illness that can cause chronic health conditions requiring comprehensive care. It may also lead to disability. 2 Long COVID impacts approximately 1 in 5 Americans adults who had a previous COVID-19 infection. 1 It can include a wide range of ongoing symptoms and conditions that can last weeks, months, or even years after COVID-19 illness. 1 Some of the common among the more than 200 identified symptoms include fatigue, brain fog, coughing, shortness of breath, heart palpitations and change in smell or taste. 3 Anyone who had a SARS-CoV-2 infection, the virus that causes COVID-19, can experience Long COVID, including children. 1 Long COVID remains a significant public health challenge with no currently available established treatments. About ANKTIVA ® (nogapendekin alfa inbakicept-pmln) The cytokine interleukin-15 (IL-15) plays a crucial role in the immune system by affecting the development, maintenance, and function of key immune cells—NK and CD8+ killer T cells—that are involved in killing cancer cells. By activating NK cells, ANKTIVA® overcomes the tumor escape phase of clones resistant to T cells and restores memory T cell activity with resultant prolonged duration of complete response. A key component in the company's BioShield platform, ANKTIVA is a first-in-class IL-15 agonist IgG1 fusion complex, consisting of an IL-15 mutant (IL-15N72D) fused with an IL-15 receptor alpha, which binds with high affinity to IL-15 receptors on NK, CD4+, and CD8+ T cells. This fusion complex of ANKTIVA® mimics the natural biological properties of the membrane-bound IL-15 receptor alpha, delivering IL-15 by dendritic cells and driving the activation and proliferation of NK cells with the generation of memory killer T cells that have retained immune memory against these tumor clones. IMPORTANT SAFETY INFORMATION INDICATION AND USAGE: ANKTIVA® is an interleukin-15 (IL-15) receptor agonist indicated with Bacillus Calmette-Guérin (BCG) for the treatment of adult patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors. WARNINGS AND PRECAUTIONS: Risk of Metastatic Bladder Cancer with Delayed Cystectomy. Delaying cystectomy can lead to the development of muscle-invasive or metastatic bladder cancer, which can be lethal. If patients with CIS do not have a complete response to treatment after a second induction course of ANKTIVA® with BCG, reconsider cystectomy. DOSAGE AND ADMINISTRATION: For Intravesical Use Only. Do not administer by subcutaneous or intravenous routes. Please see the complete Prescribing Information for ANKTIVA ® at References: Robertson MM, Qasmieh SA, Kulkarni SG, et al. The Epidemiology of Long Coronavirus Disease in US Adults. Clin Infect Dis. May 3 2023;76(9):1636-1645. U.S. Centers for Disease Control and Prevention. Long COVID Basics. July 2025. Available at U.S. Centers for Disease Control and Prevention. Long COVID Signs and Symptoms. July 2025. Available at About ImmunityBio ImmunityBio is a vertically-integrated commercial stage biotechnology company developing next-generation therapies that bolster the natural immune system to defeat cancers and infectious diseases. The Company's range of immunotherapy and cell therapy platforms, alone and together, act to drive and sustain an immune response with the goal of creating durable and safe protection against disease. Designated an FDA Breakthrough Therapy, ANKTIVA is the first FDA-approved immunotherapy for non-muscle invasive bladder cancer CIS that activates NK cells, T cells, and memory T cells for a long-duration response. The Company is applying its science and platforms to treating cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies that we believe sharply reduce or eliminate the need for standard high-dose chemotherapy. These platforms and their associated product candidates are designed to be more effective, accessible, and easily administered than current standards of care in oncology and infectious diseases. For more information, visit (Founder's Vision) and connect with us on X (Twitter), Facebook, LinkedIn, and Instagram. Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements regarding potential implications to be drawn from preliminary clinical study results, clinical trial enrollment, timing, data and potential results to be drawn therefrom, anticipated components of ImmunityBio's CancerBioShield™ platform, the potential health conditions associated with Long COVID, potential patient populations and implications thereof, the development of therapeutics for cancer and infectious diseases, potential benefits to patients, potential treatment outcomes for patients, the described mechanism of action and results and contributions therefrom, potential future uses and applications of ANKTIVA alone or in combination with other therapeutic agents across multiple tumor types and indications and for potential applications beyond oncology, potential regulatory pathways and the regulatory review process and timing thereof, the application of the Company's science and platforms to treat cancers or develop cancer vaccines, immunotherapies and cell therapies that have the potential to change the paradigm in cancer care, and ImmunityBio's approved product and investigational agents as compared to existing treatment options, among others. Statements in this press release that are not statements of historical fact are considered forward-looking statements, which are usually identified by the use of words such as 'anticipates,' 'believes,' 'continues,' 'goal,' 'could,' 'estimates,' 'scheduled,' 'expects,' 'intends,' 'may,' 'plans,' 'potential,' 'predicts,' 'indicate,' 'projects,' 'is,' 'seeks,' 'should,' 'will,' 'strategy,' and variations of such words or similar expressions. Statements of past performance, efforts, or results of our preclinical and clinical trials, about which inferences or assumptions may be made, can also be forward-looking statements and are not indicative of future performance or results. Forward-looking statements are neither forecasts, promises nor guarantees, and are based on the current beliefs of ImmunityBio's management as well as assumptions made by and information currently available to ImmunityBio. Such information may be limited or incomplete, and ImmunityBio's statements should not be read to indicate that it has conducted a thorough inquiry into, or review of, all potentially available relevant information. Such statements reflect the current views of ImmunityBio with respect to future events and are subject to known and unknown risks, including business, regulatory, economic and competitive risks, uncertainties, contingencies and assumptions about ImmunityBio, including, without limitation, (i) risks and uncertainties regarding participation and enrollment and potential results from the clinical trial described herein, (ii) whether clinical trials will result in registrational pathways, (iii) whether clinical trial data will be accepted by regulatory agencies, (iv) the ability of ImmunityBio to fund its ongoing and anticipated clinical trials, (v) the ability of ImmunityBio to continue its planned preclinical and clinical development of its development programs through itself and/or its investigators, and the timing and success of any such continued preclinical and clinical development, patient enrollment and planned regulatory submissions, (vi) potential delays in product availability and regulatory approvals, (vii) ImmunityBio's ability to retain and hire key personnel, (viii) ImmunityBio's ability to obtain additional financing to fund its operations and complete the development and commercialization of its various product candidates, (ix) potential product shortages or manufacturing disruptions that may impact the availability and timing of product, (x) ImmunityBio's ability to successfully commercialize its approved product and product candidates, (xi) ImmunityBio's ability to scale its manufacturing and commercial supply operations for its approved product and future approved products, and (xii) ImmunityBio's ability to obtain, maintain, protect, and enforce patent protection and other proprietary rights for its product candidates and technologies. More details about these and other risks that may impact ImmunityBio's business are described under the heading 'Risk Factors' in the Company's Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on March 3, 2025, and the Company's Form 10-Q filed with the SEC on August 5, 2025, and in subsequent filings made by ImmunityBio with the SEC, which are available on the SEC's website at ImmunityBio cautions you not to place undue reliance on any forward looking statements, which speak only as of the date hereof. ImmunityBio does not undertake any duty to update any forward-looking statement or other information in this press release, except to the extent required by law.
Business Wire
30 minutes ago
- Business Wire
OpenX Integrates S&P Global Mobility's Polk Automotive Solutions to Unlock Turnkey Closed-Loop Measurement for Auto Marketers, a First for the Supply Side
NEW YORK--(BUSINESS WIRE)--OpenX Technologies, Inc., one of the world's leading omnichannel supply-side platforms, today announced it has integrated with S&P Global Mobility's Polk Automotive Solutions portfolio. This direct integration brings Polk's measurement to the supply side for the first time, combining audience precision with supply path efficiency to deliver superior, measurable outcomes for auto marketers. OpenX Integrates S&P Global Mobility's Polk Automotive Solutions to Unlock Turnkey Closed-Loop Measurement for Auto Marketers, a First for the Supply-Side Share With US automotive media ad spend projected to surpass $31 billion in 2025, OpenX — through the integration of Polk's advanced analytics solutions — empowers auto buyers to measure and optimize campaigns, delivering real-time attribution tied to actual vehicle transactions. The integration also includes Polk's predictive audiences, which, unlike traditional solutions that rely on sample data or modeled assumptions, are rooted in more than 30 years of ownership history and scored and trained against census-level vehicle transactions. Together with OpenX's people-based identity graph and premium cross-inventory format, this partnership ensures greater targeting accuracy and meaningful campaign results. With OpenXSelect™, a curation and supply-side targeting platform that makes media buying easier, faster, and more precise across channels, and Polk's 2,000+ auto segments built from a rich understanding of auto buyers, media buyers get high-fidelity offline matching, insights to optimize campaigns in-flight, and accurate closed-loop measurement and attribution across CTV, display, and out-of-home campaigns. 'Our mission is to deliver the industry's best automotive insights and data that empowers our users to connect more effectively with their customers,' says Joe Kyriakoza, VP and General Manager Polk Automotive Solutions at S&P Global Mobility. 'Integrating Polk's automotive intelligence into OpenXSelect extends the reach and performance of Polk solutions, giving marketers the insights and scale needed to drive better business outcomes while streamlining campaign setup.' OpenX has led curation and supply-side targeting since 2018, when it launched the industry's first and largest independent supply-side identity graph. Today, OpenXSelect pairs premium omnichannel inventory with turnkey audience, behavioral, attention, and sustainability data and over 200,000 direct publisher sites and apps, delivering unmatched scale across CTV, native, app, and web inventory. 'This integration marks a major milestone in delivering more advanced, higher-performing tools,' said Brian Chisholm, SVP of Strategic Partnerships at OpenX. 'Supply-side targeting and curation are maturing rapidly. Targeting has been a key focus for us, and the ability to measure outcomes with Polk delivers significant advertiser value.' About OpenX OpenX is an independent omnichannel supply-side platform (SSP) and a global leader in supply-side curation, transparency, and sustainability. Through its 100% cloud-based tech stack, OpenX powers advertising across CTV, app, mobile web, and desktop, enabling publishers to deliver marketers improved performance and dynamic future-proofed solutions. With a 17-year track record of programmatic innovation, OpenX is a direct and trusted partner of the world's largest publishers, working with more than 200,000 premium publisher domains and over 100,000 advertisers. As the market leader in sustainability, OpenX was the first adtech company certified as CarbonNeutral™ and third-party verified for achieving its SBTi Net-Zero targets. Learn more at
Business Wire
30 minutes ago
- Business Wire
Genesys Xperience 2025: Engage in the Next Level of Experience
SAN FRANCISCO--(BUSINESS WIRE)-- Genesys ®, a global cloud leader in AI-Powered Experience Orchestration, today announced Xperience 2025, the premier customer experience (CX) and AI event of the year, taking place Sept. 8–10, 2025, at the Gaylord Opryland Resort & Convention Center in Nashville, Tennessee. Xperience 2025 is where the Next Level of Experience comes into focus. During the event, thousands of business leaders will gain insights and practical guidance to explore what's next in CX and how they can accelerate agentic AI orchestration to fuel growth, efficiency and customer loyalty. Genesys chairman and CEO Tony Bates will open the event by detailing how the company's vision for agentic AI and universal orchestration helps organizations deepen loyalty, increase lifetime value and accelerate revenue growth. Bates will set the stage for how AI is ushering in one of the most profound business transformations in history — enabling more effective, efficient and emotionally intelligent experiences for customers and employees. Mainstage moments from Genesys leaders include: Chief product officer Olivier Jouve will spotlight the latest in Genesys Cloud™ AI innovation and share how the company is evolving experience orchestration for what's next. Chief customer officer Scott Cravotta and senior vice president of customer engagement & advocacy Janelle Binder will be joined onstage by Genesys customers to share how they are operationalizing AI-Powered Experience Orchestration to drive loyalty and efficiency. Chief technology officer Glenn Nethercutt will explore how agentic AI is redefining CX through autonomy, reasoning and collaboration — and what guardrails enterprises need to lead with confidence. Xperience 2025 will also provide insights directly from Genesys customers, including Carmax Inc., Emirates, Fanatics, Global Payments, IONOS, M&T Bank, Nationwide Insurance, Tiffany & Co., Virgin Atlantic, Voya Financial and more. Attendees will gain access to personalized content journeys, hands-on learning, expert consultations and an immersive expo experience. Curated networking experiences, executive roundtables and focused peer discussions during the event are designed to foster strategic dialogue, surface best practices and spark actionable insights. Attendees will leave equipped with the knowledge and tools to meet rising consumer expectations, optimize performance and accelerate outcomes in an AI-powered future. In addition to the broader event programming, Xperience 2025 will feature an exclusive Executive Perspectives track — convening senior CX and technology leaders for a day of peer networking and thought leadership. On September 9, participants will hear from renowned voices shaping the future of leadership and innovation, including Wharton professor Katy Milkman, AI policy pioneer Justine Cassell and longevity expert Dr. Peter Attia. To explore the agenda and register for Xperience 2025, visit About Genesys Genesys empowers more than 8,000 organizations in over 100 countries to improve loyalty and business outcomes by creating the best experiences for their customers and employees. Through Genesys Cloud, the AI-Powered Experience Orchestration platform, Genesys delivers the future of CX to organizations of all sizes so they can provide empathetic, personalized experience at scale. As the trusted platform that is born in the cloud, Genesys Cloud helps organizations accelerate growth by enabling them to differentiate with the right customer experience at the right time, while driving stronger workforce engagement, efficiency and operational improvements. Visit © 2025 Genesys. All rights reserved. Genesys, the Genesys logo, Genesys Cloud, Genesys Cloud CX, GCXNow, Experience as a Service and AppFoundry are trademarks, service marks and/or registered trademarks of Genesys. All other company names and logos may be registered trademarks or trademarks of their respective companies.
